Multinational phase 2 trial of lenvatinib plus pembrolizumab for pretreated metastatic B3 thymoma and thymic carcinoma

There is no standard treatment for patients with platinum-refractory advanced type B3 thymoma and thymic carcinoma. The phase 2 PECATI trial, at 11 centers in France, Italy, and Spain evaluated the combination of lenvatinib and pembrolizumab in this population. The trial met its primary endpoint, with 5-month progression-free survival rate of 88.4% (90% CI 79.8-96.7). Grade 3 or 4 treatment-related adverse events were reported in 37% of patients. There were no grade 5 TRAEs. The authors conclude that lenvatinib combined with pembrolizumab showed potential as a standard treatment for pretreated advanced B3 thymoma and thymic carcinoma.